VTRS · 8-K · 20260806PR000037
Acquisition / Partnership / Divestiture
Viatris Inc · 2026-08-06 · Importance 71 · Surprise 60 · In source text
Viatris signed a definitive agreement in August 2026 to sell the global Tyrvaya product rights to Harrow for $30 million upfront and up to $70 million in commercial contingent milestone payments. It completed the sale of its Biocon Limited equity position for approximately $380 million, bringing total monetization of its Biocon Biologics stake to approximately $780 million. The company also signed a France distribution agreement with Accord Healthcare for three biosimilars and a co-promotion partnership with Idorsia for Quviviq in Italy and Canada.
Key facts
- Viatris completed sale of its equity position in Biocon Limited in July for pre-tax total consideration of approximately $380 million; this completes monetization of its stake in Biocon Biologics Limited for a total of approximately $780 million source
- In August, Viatris signed a definitive agreement to sell global product rights for Tyrvaya to Harrow, Inc. for an upfront payment of $30 million and an additional $70 million in commercial contingent milestone payments source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | contingent | +0.1% | In August, Viatris signed a definitive agreement to sell global product rights for Tyrvaya to Harrow, Inc. for an upfront payment of $30… |
| cash | positive | realized | — | Viatris completed sale of its equity position in Biocon Limited in July for pre-tax total consideration of approximately $380 million;… |
| cash | positive | committed | — | In August, Viatris signed a definitive agreement to sell global product rights for Tyrvaya to Harrow, Inc. for an upfront payment of $30… |